Loading
Led CLL13 (GAIA), showing venetoclax-based fixed-duration therapy beats chemoimmunotherapy in fit CLL patients.
Barbara Eichhorst was principal investigator of CLL13/GAIA, the trial showing venetoclax plus obinutuzumab, with or without ibrutinib, achieves higher MRD-negativity and longer progression-free survival than FCR or BR in fit patients with untreated CLL, extending fixed-duration therapy to the fit population. She led CLL10 (FCR versus BR) and chairs the ESMO CLL guidelines.
Shares Uniklinik Köln (CIO), BCL-2, CD20, Venetoclax and the tags cll, venetoclax.
Shares BCL-2, CD20, Venetoclax, MRD / molecular residual disease testing and the tags cll, venetoclax.
Shares BCL-2, Venetoclax, MRD / molecular residual disease testing, Chronic lymphocytic leukaemia and the tags cll, guidelines.
Shares BCL-2, Venetoclax, MRD / molecular residual disease testing, Chronic lymphocytic leukaemia and the tag cll.
Shares Uniklinik Köln (CIO), CLL13 / GAIA, BCL-2, CD20.
Shares CLL13 / GAIA, BCL-2, CD20, Venetoclax.
Shares BCL-2, Venetoclax, MRD / molecular residual disease testing and the tag venetoclax.
Shares BCL-2, Venetoclax, Chronic lymphocytic leukaemia and the tag cll.